FILE - Packaging for AbbVie's drug, Humira. Patients who take the autoimmune disease treatment can get some price relief when lower-cost, biosimilar versions are included on health plan formularies.

AbbVie’s popular arthritis drug Humira is a powerhouse, producing $14 billion in annual sales to make up 60 percent of the drugmaker’s revenue. However, generic versions of the drug are around the ...

Humira, AbbVie’s anti-inflammatory drug that has dozens of patents and $114 billion in U.S. sales, has a tight grasp on its market. That’s soon to change, The New York Times reported Jan. 28. Since ...